President Trump today announced an initiative to address the opioid crisis focused on education, awareness and preventing overprescribing; developing non-addictive alternatives to opioids; cutting off the flow of illicit drugs; and expanding opportunities for proven treatments. Addressing an audience in New Hampshire, he said the administration will “seek legislative changes to the law prohibiting Medicaid from reimbursing residential treatment at certain facilities with more than 16 beds” and, in the meantime, “continue approving state Medicaid demonstration projects that waive these barriers to inpatient treatment,” both actions that AHA supports. Chairmen of relevant committees in Congress have said they plan to enact comprehensive legislation by Memorial Day. AHA last week submitted policy recommendations to House Ways and Means Committee leaders as they begin developing Medicare-related legislation on the issue, and has submitted recommendations to other committees of jurisdiction as well. On Wednesday, the House Energy and Commerce Committee will hold the first of two days of hearings on more than 20 bills aimed at combatting the opioid crisis.

Related News Articles

Headline
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
The AHA and other national hospital organizations Sept. 5 urged Senate and House leadership to act on preventing Medicaid Disproportionate Share Hospital…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…